Cardiovascular Outcome trial of NN9924

Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes - SOUL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224852

Enrollment

400

Registered

2019-09-03

Start date

2019-08-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

investigational material(s) Generic name etc : INN of investigational material : - Therapeutic category code : 249 Other hormone preparations (including antihormone preparations) Dosage and Administr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with type 2 diabetes at high risk for cardiovascular disease

Exclusion criteria

Exclusion criteria: Severe heart failure, Severe psychological disorder, Other

Design outcomes

Primary

Measure	Time frame
Time to first occurrence of MACE, a composite endpoint consisting of CV death, non-fatal myocardial infarction, non-fatal stroke	—

Countries

Algeria, Argentina, Austria, Belgium, Brazil, Canada, China, Colombia, Croatia, Czech Republic, Denmark, France, Germany, Hong Kong, India, Israel, Italy, Malaysia, Mexico, Netherlands, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States

Contacts

Public Contactregister clinical tiral infomartion

Novo Nordisk Pharma Ltd.

JPHC_clinical_trials@novonordisk.com+81-3-6266-1000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026